It has been reported that
immunosuppressant FK506 inhibited ischemic neuronal injury in forebrain
ischemia or transient focal
cerebral ischemia, but the mechanisms of the
neuroprotective effect have not been clarified. In permanent focal
cerebral ischemia, we investigated whether
FK506 caused remission of
brain infarction, and how mechanism was concerned. Male Balb/c mice were subjected to permanent middle cerebral artery (MCA) occlusion. They were treated with 1.0 or 3.0 mg/kg
FK506 or vehicle 30 min before
ischemia.
Infarct volume was assessed by
2,3,5-triphenyltetrazolium chloride (TTC) method after 24 h.
Cytochrome c release from mitochondria was evaluated by Western blotting and immunocytochemistry after
ischemia. Simultaneously, the immunoreactivity of total and phosphorylated BAD was also studied using immunocytochemistry. We demonstrated that pretreatment with 3.0 mg/kg
FK506 salvaged the tissue damage in the
infarct rim and significantly reduced
infarct volume to 75.5% (P<0.05), and
FK506 inhibited
cytochrome c release on 6 h after
ischemia for Western blot analysis (P<0.05). Immunocytochemical study showed that permanent MCA occlusion increased the amount of
cytochrome c and total BAD in the cytosol, but not phosphorylated BAD, in the ischemic core and the
infarct rim as early as 1 h after
ischemia, and
FK506 inhibited the increases in the
infarct rim. The results suggest that
FK506 may, at least in part, ameliorate tissue damage due to permanent focal
cerebral ischemia in the
infarct rim through maintaining BAD turnover and inhibiting
cytochrome c release from mitochondria.